 |
|
|
|
 |
|
|
| Article 1 to 9 out of 9 concerning Ambion, Inc.
|
-
Applied Biosystems Completes Acquisition of the Research Products Division of Ambion, Inc.
(06 Mar 2006)
Applied Biosystems Group, an Applera Corporation business, announced that it has completed the previously announced acquisition of the Research Products Division of Ambion, Inc., a provider of products for the study and analysis of ribonucleic acid ...
-
Applied Biosystems to Acquire the Research Products Division of Ambion, Inc.
(29 Dec 2005)
Applied Biosystems Group, an Applera Corporation business, and Ambion, Inc. announced they have signed a definitive agreement whereby Applied Biosystems will acquire the Research Products Division of Ambion, a premium supplier of RNA-based reagents ...
-
Ambion and Rosetta Genomics Announce Licensing and Commercialization Deal To Advance microRNA Research
(13 Sep 2005)
Agreement provides Ambion access to Rosetta's database of proprietary microRNA sequences for a range of applications in medical research
Rosetta Genomics Ltd. and Ambion, Inc. announced a collaborative licensing agreement that will provide Ambion access to proprietary microRNA (miRNA) sequences discovered and owned by Rosetta Genomics. The agreement enables Ambion to adapt its ...
-
Cenix BioScience Delivers on Target Discovery Collaboration
(11 Aug 2005)
Cenix BioScience GmbH (Dresden) announced that it has delivered a collection of potential novel therapeutic targets to one of its pharmaceutical partners, Bayer HealthCare AG (Leverkusen). The targets were identified as part of a RNAi-based ...
-
Ambion to Provide MitoCheck Consortium a Genome-Wide siRNA Library
(13 Jul 2005)
Ambion (Austin, Texas, USA) and Ambion (Europe) Ltd. announced an agreement with the MitoCheck consortium to provide a genome-wide siRNA library targeting every human gene. MitoCheck, which is an EU-funded integrated, multinational research ...
-
Qiagen and Invitrogen Revealed as Top Suppliers in the RNA Purification Market
(30 Jun 2005)
A recent survey reveals that more than 60% of scientists cited Qiagen as their primary supplier of RNA purification kits and more than 45% identified Invitrogen as their primary supplier of commercial reagents. With almost one-third of scientists ...
-
Alnylam Grants Ambion License to Fundamental RNAi Patents for Applications in the Research Products Market
(13 Jun 2005)
Alnylam Pharmaceuticals, Inc. announced that it has granted Ambion, Inc. a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family covers ...
-
Ambion and Applied Biosystems Combine siRNA and Real-Time PCR Products
(20 Jan 2004)
Ambion announced that it has entered into an agreement with Applied Biosystems, an Applera Corporation business, to exclusively co-market Ambion's siRNA products and Applied Biosystems' real-time PCR reagents to offer a complete solution for ...
-
Ambion Releases siRNA Libraries, Including a Highly Validated Kinase siRNA Library
(15 Dec 2003)
Ambion, The RNA Company, announced the launch and availability of two siRNA libraries: the first targets 597 human kinases and the second targets 441 human G protein-coupled receptors (GPCRs). The kinase siRNA library includes one or more ...
|
|
|
|
|
Top
